



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/791,270 Confirmation No. : 8940
First Named Inventor : Masaaki NOMURA
Filed : March 3, 2004
TC/A.U. : 1615
Examiner : (To Be Assigned)
Docket No. : 100598.53322US
Customer No. : 23911
Title : Pharmaceutical Hard Capsule Containing Inorganic Substance

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R §§ 1.97 AND 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This supplements the Information Disclosure Statement submitted in the above-identified application on July 26, 2004.

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a corresponding European Search Report dated June 23, 2005 citing documents AA-AH together with an English-language version (if not already included) of that portion of the Search Report indicating the degree of relevance found by the foreign office.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits. Furthermore, I hereby


certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement and therefore no fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

If necessary, the paper should be considered as a petition for consideration of the Information Disclosure Statement under 37 C.F.R. § 1.97(d)(1) and that the petition fee set forth in 37 C.F.R. § 1.17(p) in accordance with 37 C.F.R. § 1.97(d)(2) should be charged to Deposit Account 05-1323, Attorney Docket No.: 100598.53322US.


Respectfully submitted,

August 25, 2005



Jeffrey D. Sanok
Registration No. 32,169

CROWELL & MORING LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
JDS:kac



Part V Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/791,270
				Filing Date	March 3, 2004
				First Named Inventor	Masaaki NOMURA
				Art Unit	1615
				Examiner Name	(To Be Assigned)
Sheet	1	of	1	Attorney Docket Number	100598.53322US

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials'	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ –Number ⁴ –Kind Code ⁵ (if known)				
	AC	WO 00/76520 A1	12-21-2000	Hanmi Pharm Co., Ltd.		
	AD	WO 00/59475 A1	10-12-2000	Lipocene, Inc.		
	AE	WO 99/44614 A1	09-10-1999	DaeWoong Pharmaceutical Co., Ltd.		
	AF	DE 101 44 557 A1	03-27-2003	Bayer AG		
	AG	WO 03/037379 A1	05-08-2003	Degussa AG		
	AH	EP 0 722 732 A1	07-24-1996	Mitsui Toatsu Chemicals, Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.